Figure 1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2025)
Figure 2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2025)
Figure 3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2025)
Figure 4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2025)
Figure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2025)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2025)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2025)
Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2025)
Supplementary Figure S4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2025)
Supplementary Figure S5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2025)
Supplementary Figure S6 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2025)
Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2025)
Immunopeptidomics Workflow for Isolation and LC-MS/MS Analysis of MHC Class I-Bound Peptides Under Hypoxic Conditions.
Estephan H. et al, (2025), Bio Protoc, 15
High-Affinity Peptide-Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain.
Platt MA. et al, (2025), Chemistry
A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications.
Hacker L. et al, (2025), Mol Oncol, 19, 3003 - 3022
PD-1/PD-L1 inhibitors in advanced, unresectable esophageal squamous-cell carcinoma: A meta-analysis of their effects across patient subgroups
Beshr MS. et al, (2025), Critical Reviews in Oncology Hematology, 215
High throughput mutational characterization of the GPCR ligand C5a using yeast display and deep sequencing.
Xu Y. et al, (2025), Structure
Reversible Enzymatic Switching of the Oxidation State of a EuIII/II Complex Controls Relaxivity.
Sarson ET. et al, (2025), J Am Chem Soc